Pharmaceutical Company Mylan Settles False Claims Lawsuit With Massachusetts AG for $2.6M

Massachusetts has prevailed in a False Claims Act lawsuit against pharmaceutical giant Mylan, which was accused of reporting inflated prices to drug price-reporting services, causing the Massachusetts Medicaid program to pay inflated prices for Medicaid beneficiaries' prescriptions, according to a news release by the Massachusetts Attorney General's Office.

Massachusetts' Medicaid program relies on prices reported by pharmaceutical companies to determine what it will pay to pharmacies for ingredient costs for prescription drugs. Mylan has agreed to pay more than $2.6 million to settle the allegations it had reported inflated prices of its drugs. The settlement resolves claims related to drugs Mylan manufactured and sold from 1998-2003, including Clozapine, Phenytoin Sodium and Lorazapam.

In agreeing to the settlement, Mylan is not admitting any wrongdoing.

Read the news release about Mylan's settlement with Massachusetts.

Read other coverage about pharmaceutical fraud:

- Advocacy Group: Pharmaceutical Companies Top List of DOJ Settlements

- Connecticut Wins $15M From Pharmaceutical Company McKesson in Drug Pricing Lawsuit

- Drug Maker Sandoz Settles Drug Pricing Allegations, Agrees to Pay $1.65M to Idaho

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers